Table 2.
Correlation of FCGR3A expression with clinicopathological features in PCa patients.
| Clinical features | TMA | TCGA | ||||||
|---|---|---|---|---|---|---|---|---|
| Case | Low, n (%) | High, n (%) | P | Case | Low, n (%) | High, n (%) | P | |
| Tissue | ||||||||
| Cancer | 70 | 32 (45.71) | 38 (54.29) | 0.397 | 427 | 213 (49.88) | 214 (50.12) | – |
| Non-cancer | 10 | 6 (60.00) | 4 (40.00) | – | 0 | – | – | – |
| Age (years) | ||||||||
| ≤60 | 14 | 7 (50.00) | 7 (50.00) | 0.837 | 190 | 105 (55.26) | 85 (44.74) | 0.047 * |
| >60 | 66 | 31 (46.97) | 35 (53.03) | – | 237 | 108 (45.57) | 129 (54.43) | – |
| Gleason score | ||||||||
| ≤8 | 46 | 22 (47.83) | 24 (52.17) | 0.623 | 300 | 171 (57.00) | 129 (43.00) | <0.001 *** |
| >8 | 24 | 10 (41.67) | 14 (58.33) | – | 127 | 42 (33.07) | 85 (66.93) | – |
| Serum PSA levels (ng/ml) | ||||||||
| ≤2 | – | – | – | – | 378 | 196 (51.85) | 182 (48.15) | 0.003 ** |
| >2 | – | – | – | – | 35 | 9 (25.71) | 26 (74.29) | – |
| Pathological grade | ||||||||
| pT1-pT2 | 4 | 3 (75.00) | 1 (25.00) | 0.213 | – | – | – | – |
| pT3 | 65 | 28 (43.08) | 37 (56.92) | – | – | – | – | – |
| Tumor stage | ||||||||
| T1 | 0 | – | – | - | 153 | 92 (60.13) | 61 (39.87) | 0.006 ** |
| T2 | 42 | 16 (38.10) | 26 (61.90) | 0.030 * | 155 | 75 (48.39) | 80 (51.61) | – |
| T3 | 14 | 10 (71.43) | 4 (28.57) | – | 48 | 16 (33.33) | 32 (66.67) | – |
| T4 | 0 | – | – | – | 1 | 0 (0.00) | 1 (100.00) | – |
| Lymph nodemetastasis | ||||||||
| N0 | 56 | 26 (46.43) | 30 (53.57) | – | 303 | 155 (51.16) | 148 (48.84) | <0.001 *** |
| N1 | 0 | – | – | – | 69 | 20 (28.99) | 49 (71.01) | – |
| Distant metastasis | ||||||||
| M0 | 56 | 26 (46.43) | 30 (53.57) | – | 401 | 200 (49.88) | 201 (50.12) | 0.568 |
| M1 | 0 | – | – | – | 3 | 1 (33.33) | 2 (66.67) | – |
＊means the difference is significant at the 0.05 level ,** means the difference is significant at the 0.01 level, *** means the difference is significant at the 0.01 level.